Mind Pharmaceuticals
- | Biotech or pharma, therapeutic R&D
Mind Pharmaceuticals is a clinical stage company based in New Haven focused on using Psychedelics for hard to treat CNS diseases founded on research done at Yale University.
Our lead product, MIND001, is a Synthetic formulation of DMT for Treatment Resistant Depressiion. A Phase 1/2 trial with 10 patients has been completed and
another one with 60 patients is underway. With a new formulation of DMT that minimizes the psychedelic effect and at the same time retain efficacy, we will conduct a small trial to establish Proof of concept in Humans.
In addition we have we other indications-
1. Prevention of Onset of Migraine / Cluster Headaches (Non-Psychedelic Dose of Psilocybin) with a completed Phase 1/2 trial with 12 Patients
2. Treatment of Alcohol Abuse Disorder. with a Phase ½ trial currently underway at the Yale University.
All these indications are licensed from Yale University in New Haven CT. We are looking to raise money for advancing our clinical pipeline.
Address
New HavenConnecticut
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}